• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

兔体内致癌性谷氨酸热解产物暴露水平监测仪

Exposure level monitor of a carcinogenic glutamic acid pyrolysis product in rabbits.

作者信息

Yin Y, Wada O, Manabe S

机构信息

Department of Hygiene and Preventive Medicine, Faculty of Medicine, University of Tokyo, Japan.

出版信息

Mutat Res. 1989 Nov;215(1):107-13. doi: 10.1016/0027-5107(89)90223-6.

DOI:10.1016/0027-5107(89)90223-6
PMID:2811912
Abstract

In order to determine a suitable indicator for estimating the exposure levels of the dietary carcinogen 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1), a carcinogenic glutamic acid pyrolysis product, the levels of Glu-P-1 bound to blood components were monitored for 8 weeks by a high-performance liquid chromatography method after the dietary carcinogen was administered as single oral doses (0.2-50 mg) to rabbits. In all rabbits dosed with Glu-P-1, Glu-P-1 in erythrocytes was detectable even on day 42 after administration. Glu-P-1 in plasma disappeared faster than did Glu-P-1 in erythrocytes. Glu-P-1 levels in rabbit hemoglobin were linearly related to administered doses at all points of time investigated. The results suggest that Glu-P-1 covalently bound to hemoglobin is very suitable for monitoring long-term exposure levels.

摘要

为了确定一种合适的指标来估算膳食致癌物2-氨基-6-甲基二吡啶并[1,2-a:3',2'-d]咪唑(Glu-P-1,一种致癌性谷氨酸热解产物)的暴露水平,在给兔子单次口服膳食致癌物(0.2 - 50毫克)后,采用高效液相色谱法对与血液成分结合的Glu-P-1水平进行了8周的监测。在所有给予Glu-P-1的兔子中,即使在给药后第42天,红细胞中的Glu-P-1仍可检测到。血浆中的Glu-P-1比红细胞中的Glu-P-1消失得更快。在所研究的所有时间点,兔血红蛋白中的Glu-P-1水平与给药剂量呈线性相关。结果表明,与血红蛋白共价结合的Glu-P-1非常适合用于监测长期暴露水平。

相似文献

1
Exposure level monitor of a carcinogenic glutamic acid pyrolysis product in rabbits.兔体内致癌性谷氨酸热解产物暴露水平监测仪
Mutat Res. 1989 Nov;215(1):107-13. doi: 10.1016/0027-5107(89)90223-6.
2
Exposure level monitor of 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole, a dietary carcinogen, in rabbits.家兔体内膳食致癌物3-氨基-1,4-二甲基-5H-吡啶并[4,3-b]吲哚的暴露水平监测
Environ Mol Mutagen. 1989;14(1):34-41. doi: 10.1002/em.2850140107.
3
Accumulation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole and 2-aminodipyrido[1,2-a:3',2'-d]imidazole, carcinogenic glutamic acid pyrolysis products, in plasma of patients with uremia.尿毒症患者血浆中2-氨基-6-甲基二吡啶并[1,2-a:3',2'-d]咪唑和2-氨基二吡啶并[1,2-a:3',2'-d]咪唑(致癌性谷氨酸热解产物)的蓄积。
Cancer Res. 1987 Nov 15;47(22):6150-5.
4
Urinary excretion levels of carcinogenic glutamic acid pyrolysis products and their N-acetyl derivatives in humans.人体内致癌性谷氨酸热解产物及其N-乙酰衍生物的尿排泄水平。
Nihon Eiseigaku Zasshi. 1991 Oct;46(4):922-9. doi: 10.1265/jjh.46.922.
5
N-acetyl derivative as the major active metabolite of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole in rat bile.N-乙酰衍生物作为2-氨基-6-甲基二吡啶并[1,2-a:3',2'-d]咪唑在大鼠胆汁中的主要活性代谢物。
Mutat Res. 1986 Sep;175(1):23-8. doi: 10.1016/0165-7992(86)90140-5.
6
Presence of carcinogenic glutamic-acid pyrolysis products in human cataractous lens.人类白内障晶状体中致癌性谷氨酸热解产物的存在。
Ophthalmic Res. 1988;20(1):20-6. doi: 10.1159/000266251.
7
Carcinogenic glutamic acid pyrolysis product in the dialysate of uremic patients treated by continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析治疗的尿毒症患者透析液中的致癌性谷氨酸热解产物。
Clin Nephrol. 1988 Aug;30(2):73-8.
8
In vitro and in vivo N-acetylation of carcinogenic glutamic acid pyrolysis products in humans.
Carcinogenesis. 1988 Dec;9(12):2179-84. doi: 10.1093/carcin/9.12.2179.
9
Detection of N-acetyl derivative of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1) in Glu-P-1-injected rats.在注射了2-氨基-6-甲基二吡啶并[1,2-a:3',2'-d]咪唑(Glu-P-1)的大鼠中检测Glu-P-1的N-乙酰衍生物。
Mutat Res. 1988 Feb;207(2):63-7. doi: 10.1016/0165-7992(88)90043-7.
10
Detection of carcinogenic glutamic acid pyrolysis products in cigarette smoke condensate.
Carcinogenesis. 1990 Jun;11(6):1001-3. doi: 10.1093/carcin/11.6.1001.